Participated · Series B · Aug 2026

Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.

Participated · Series A · Jul 2026

Flexell Space develops next-generation space solar solutions and announced a $20 million Series A on July 14. The company is identified in the press release as being based in Uiwang, South Korea. Public reporting about the round does not include specifics on product roadmaps, customers, revenues, or other operating metrics. The articles also do not disclose how the company plans to deploy the new capital. No information about prior funding rounds or valuation was provided in the cited coverage.

Led · Equity · May 2026

Coinone is a South Korean cryptocurrency exchange led by CEO Cha Myunghun. The company has signaled strategic focus areas including stablecoins and tokenized securities. Following the announced investment, management control is expected to remain with CEO Cha, who would hold 27.8% of shares, while Com2uS Holdings and affiliates would retain roughly 25%. The new investors, OKX Ventures and Korea Investment & Securities, would each hold about 19.6% post-deal. The transaction is positioned as one of the larger recent investments by a global crypto firm into Korea’s digital asset sector. No revenue, user metrics, or specific financial performance figures were disclosed in the articles.

Participated · Series B · Feb 2026

Galux leverages its proprietary GaluxDesign platform, which integrates deep-learning with biophysical principles, to design high-affinity antibodies and other proteins from scratch. The platform has already produced antibodies whose AI-predicted structures align closely with cryo-EM data, validating its precision and generalizability. Galux is expanding the technology to harder target classes such as GPCRs and ion channels while tightly coupling AI modeling with wet-lab feedback to speed iteration. The company has formed co-development partnerships with Celltrion, LG Chem, and most recently Boehringer Ingelheim to broaden its pipeline and global reach. Proceeds from the latest financing will enhance the AI engine, grow R&D infrastructure, and advance proprietary programs into preclinical validation. Since its 2022 $18 million Series A, Galux has hit multiple R&D and business milestones, helping it secure the follow-on funding. Cumulatively, the company has raised $47 million to date.

Led · Equity · Jun 2025

Mezzion is advancing udenafil through a Fontan-focused development program that includes completed Phase I/II and extension studies, a completed Phase III FUEL trial, and the ongoing global Phase III FUEL-2 confirmatory study. Udenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that Mezzion is evaluating to improve hemodynamics and exercise capacity in patients with Fontan physiology. The company positions udenafil as a potential first-in-class, indication-specific pharmacologic option for a population with no approved therapies. Mezzion has built a clinical infrastructure across its two Phase III programs and is using the recent institutional financing to sustain enrollment and operational activities for FUEL-2. Mezzion operates as the U.S. subsidiary of South Korean Mezzion Pharma Co., Ltd.